As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Repare Therapeutics Inc. The largest reported stake is Shay Capital LLC's, at 6.7%. 5 filings are on record since November 21, 2025 (Schedule 13G, January 27, 2026).
Sell to companies like Repare Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Blue Owl Capital Holdings LP · Percent: 0% · SCHEDULE 13G/A
- · Holder: Biotechnology Value Fund L P · Percent: 0% · SCHEDULE 13D/A
- · Holder: Shay Capital LLC · Percent: 6.7% · SCHEDULE 13G
- · Holder: Biotechnology Value Fund L P · Percent: 24% · SCHEDULE 13D/A
- · Holder: Versant Venture Capital V, L.P. · Percent: 0.2% · SCHEDULE 13D/A
Repare Therapeutics Inc. has 5 Schedule 13D or 13G filings on record since 2025-11-21. 1 holder's latest filing reports 5% or more of common shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Shay Capital LLC | 6.7% | 2,870,141 | SCHEDULE 13G, 2026-01-27 | 2026-01-20 |
| Versant Venture Capital V, L.P. | 0.2% | 0 | SCHEDULE 13D/A, 2025-11-21 | 2025-11-19 |
| Biotechnology Value Fund L P | 0% | 0 | SCHEDULE 13D/A, 2026-01-30 | 2026-01-28 |
| Blue Owl Capital Holdings LP | 0% | 0 | SCHEDULE 13G/A, 2026-05-14 | 2026-03-31 |
Holding shares or following this stake? See who's behind Repare Therapeutics Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Repare Therapeutics Inc. and the records around it.
Companies that share a holder
- Shay Capital LLC also filed stake reports on 7 other companies: Xponential Fitness, Inc. (Jun 2026), DUOS TECHNOLOGIES GROUP, INC. (May 2026), A2Z CUST2MATE SOLUTIONS CORP. (Apr 2026)
- Blue Owl Capital Holdings LP also filed stake reports on 10 other companies: Context Therapeutics Inc. (Aug 2026), enGene Therapeutics Inc. (Aug 2026), Aktis Oncology, Inc. (May 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Watch Repare Therapeutics Inc.
Get an email when Repare Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Repare Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Repare Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Repare Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Biotechnology Value Fund L P
Item 4 is hereby amended to add the following: Effective January 28, 2026, the Issuer was acquired by Xeno Acquisition Corp. ("Purchaser"), a wholly-owned subsidiary of XenoTherapeutics, Inc. ("Xeno"), pursuant to an Arrangement Agreement, dated as of November 14, 2025 (the "Agreement"), under the Business Corporations Act (Quebec), by and among the Issuer, Xeno, Purchaser, and solely for limited purposes, XOMA Royalty Corporation, pursuant to which Purchaser agreed to acquire all of the issued and outstanding Shares of the Issuer. Pursuant to the Agreement, among other things, the Purchaser acquired all of the issued and outstanding Shares of the Issuer in exchange for: (i) $2.20 in cash per Share and (ii) one contingent value right per Share for potential cash payments. Accordingly, the Reporting Persons ceased to beneficially own any securities of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2026-01-30
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-21 | Versant Venture Capital V, L.P. | 0.2% | SCHEDULE 13D/A |
| 2025-11-24 | Biotechnology Value Fund L P | 24% | SCHEDULE 13D/A |
| 2026-01-27 | Shay Capital LLC | 6.7% | SCHEDULE 13G |
| 2026-01-30 | Biotechnology Value Fund L P | 0% | SCHEDULE 13D/A |
| 2026-05-14 | Blue Owl Capital Holdings LP | 0% | SCHEDULE 13G/A |
Questions about who owns Repare Therapeutics Inc.
Who owns Repare Therapeutics Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Repare Therapeutics Inc.: Shay Capital LLC (6.7%, Schedule 13G, filed 2026-01-27).
When did Shay Capital LLC buy into Repare Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Shay Capital LLC on this page is the Schedule 13G, filed 2026-01-27, reporting 6.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Repare Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.